Abstract
OBJECTIVE:
To describe the prevalence, demography and clinical characteristics of patients who were colonized or infected with methicillin-resistant Staphylococcus aureus (MRSA) in 1998 at King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
PATIENTS AND METHODS:
Results of MRSA-positive cultures of clinical specimens obtained as part of investigations for suspected infections were retrieved from the King Abdulaziz University Hospital Infection Control Department's records. Charts of patients were reviewed.
RESULTS:
Of 292 S aureus isolates identified, 111 (38%) were MRSA, or 6.0 MRSA isolates/1000 admissions, which represented a marked increase over MRSA prevalence in 1988 (less than 2%). Nosocomial acquisition occurred in 74.8% of isolates. All age groups were affected, but 45.9% of patients were in the 'extremes of age' group (younger than one or older than 60 years of age). The prevalence was highest in the medical ward (27%), followed by the paediatrics combined medical and surgical ward (20.7%), the outpatient department (18%), the adult surgical ward (17.1%) and the intensive care units (17.1%). Two-thirds (66.7%) of cases represented infection and the remainder represented colonization. Surgical wounds (31.1%), the chest (27%) and endovascular catheters (20.3%) were the most common sites of infection. Bacteremia occurred in 27% of patients. Local signs (68.9%) and fever (60.8%) were the most common clinical manifestations. Respiratory distress and septic shock occurred in 28.4% and 6.8% of cases, respectively. Of 74 patients with MRSA infection and 37 patients with MRSA colonization, 91.9% and 56.8% received antibiotics in the preceding six weeks, respectively (P<0.0001). The total mortality of patients with MRSA infection was 60.8%; 37.8% of deaths were the result of MRSA infection and 23% were the result of other diseases.
CONCLUSIONS:
The prevalence of MRSA is high and rapidly increasing at King Abdulaziz University Hospital, as it is worldwide. Control measures to prevent the spread of MRSA in hospitals should continue with reinforcement of hygienic precautions and development of policies to restrict the use of antibiotics.
Key Words: Colonization, Infection, MRSA, Saudi Arabia, Staphylococcus aureus
Staphylococcus aureus is one of the most common pathogens, known for causing a variety of infections ranging from relatively benign skin infections to life-threatening systemic illnesses such as pneumonia, endocarditis, septic arthritis, osteomyelitis and subcutaneous or visceral abscesses. S aureus is usually sensitive to cloxacillin (or methicillin), amoxicillin/clavulinate, first-generation cephalosporins, erythromycin, clindamycin and glycopeptides, such as vancomycin and teicoplanin. Methicillin-resistant S aureus (MRSA) is important because it is also usually resistant to the aforementioned antibiotics, with the exception of glycopeptides, which can only be administered intravenously. MRSA is primarily a nosocomial pathogen that emerged in the 1980s as a major cause of infection and colonization in hospitalized patients (1,2). More recently, this organism has been implicated as a cause of community-acquired infections in people with recognized predisposing risk factors, such as recent contact with a health care facility or nursing home residence, or parenteral substance abuse (3-7). Community-acquired MRSA infections in the absence of identified risk factors have also been increasingly reported (7-12). The prevalence of MRSA has increased worldwide over the past decade, with marked variations in different regions. It is generally high in the United States (13), southern European countries (14,15) and Japan (16), but is low (less than 10% of S aureus isolates) in Sweden, Denmark and the Netherlands (14,17,18). In the United States, the prevalence of MRSA increased from 2% in 1974 to approximately 50% in 1997 (19-21). In England and Wales, resistance to methicillin among S aureus isolates recovered from blood or cerebrospinal fluid was stable at about 1.5% of isolates from 1989 to 1991, but increased thereafter to 13.2% in 1995 (22). Currently, in hospitals in the United Kingdom, the prevalence of MRSA has reached epidemic levels, and incidents involving MRSA have risen 12-fold since 1991 and were responsible for 37% of all S aureus infections in 1999, compared with only 3% in 1991 (23). A prevalence of more than 30% was also observed in other southern European countries, including Spain, France and Italy (14). A high prevalence of MRSA has also been reported from Malasia (24), Ethiopia (25) and other developing countries such as Kenya, Sri Lanka and Tunisia (26).
The prevalence of MRSA in Saudi Arabia is not well defined. The present study describes the prevalence of MRSA, and the demographic and clinical characteristics of patients who were colonized or infected with this organism in 1998 at King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
DATA AND METHODS
Institution and patient population
The King Abdulaziz University Hospital is a tertiary care teaching hospital with a bed capacity of 265. The hospital had 18,492 admissions in 1998, the year of the present retrospective review. From 1978 to 1996, the hospital was run in temporary buildings. In late 1996, the hospital moved to permanent buildings. Hospital units included adult and paediatric medical, surgical and intensive care units, and an obstetrics and gynecology unit. The hemodialysis unit was not open during the study period, and there is, as yet, no burn unit. MRSA infections were treated with vancomycin. Patients with MRSA-positive cultures from any body specimen were identified from January 1, 1998 to December 31, 1998 for the present review.
Data collection
During the study period, specimens for bacterial culture were obtained as part of septic screening for suspected infections. Surveillance cultures specific for MRSA colonization were not completed during this period. All MRSA-positive culture results were obtained from the Infection Control Department's records. MRSA isolated from more than one site (eg, sputum and blood) from the same patient was counted only once. Charts of all patients with positive cultures were reviewed using standardized data collection methods. Information collected included patient demographics, mode of acquisition (nosocomial- or community-acquired), hospital units where patients stayed, comorbidities, surgery and other invasive procedures, presence of foreign devices, receipt of prophylactic or therapeutic antibiotics in the preceding six weeks, previous hospitalization, clinical significance of MRSA (colonization versus infection), site and clinical manifestations of infections, complications, and outcome.
Microbiological methods
Susceptibility testing of S aureus isolates to oxacillin was performed using a 1 μg oxacillin disk diffusion method (Oxoid Limited, United Kingdom) according to published guidelines (27). Oxacillin resistance was demonstrated by a zone of inhibition of 10 mm or less. Strains with borderline zones of inhibition (11 mm to 12 mm) were tested by E-test (AB Biodisk, Sweden) to determine the minimum inhibitory concentration (MIC). Strains with MICs of 4 μg/mL or greater were considered to be resistant, those with MICs of 2 μg/mL or less were considered to be sensitive, and those with MICs between 2 μg/mL and 4 μg/mL were considered to be intermediate (28).
Definitions
MRSA isolates were considered to be community acquired if they were recovered within 72 h of admission, and nosocomial if they were recovered after that period.
The clinical significance of MRSA isolation from different body specimens was classified as either infection or colonization based on the presence or absence of a potential source of MRSA infection, the patient's clinical status and other relevant data. In the absence of any potential source or clinical evidence of infection, MRSA was considered to be colonizing the site from which a specimen was obtained.
The source of infection was determined on the basis of clinical evidence and recovery of MRSA from an infected site.
Outcome of patients with MRSA infection was classified into four categories: recovery without complications, recovery following complications such as septic shock or respiratory failure, death due to MRSA infection, or death unrelated to MRSA infection. MRSA-attributable mortality was defined as death directly related to clinically and microbiologically documented MRSA infection or any of its complications (eg, septic shock and acute respiratory distress syndrome).
Data analysis
The Statistical Package for Social Sciences program (SPSS, Inc, United States) was used for data analysis. Yates-corrected Χ2 test was used for comparison of proportions (categorical data).
RESULTS
The total number of S aureus isolates that were isolated during the study period was 292, of which 111 (38%) were MRSA isolated from 111 patients, which translates to six (111/18,492 x 1000) MRSA isolates/1000 admissions. Twenty-eight (25.2%, or 1.5/1000 admissions) isolates were community acquired and 83 (74.8%) isolates were nosocomial. Sixty-five (58.6%) patients were male and 46 (41.4%) were female, with a mean age of 31.8 ± 25.8 years. Twenty (18%) patients were younger than one month of age, nine (8.1%) were between one and 12 months of age, 60 (54.1%) were between one and 60 years of age, and 22 (19.8%) were older than 60 years of age. Fifty-three (47.7%) patients were citizens of Saudia Arabia and 58 (52.3%) were not. The clinical characteristics of patients are summarized in Table 1. MRSA caused infection in 74 (66.7%) cases, and in the remaining 37 (33.3%) patients, it represented colonization. Surgical site infections (31.1%), pneumonia (27%) and endovascular catheter infections (20.3%) were the most common types of infection. Bacteremia occurred in 20 (27%) patients with microbiologically documented primary sites of MRSA infection. Local signs (68.9%), such as erythema, purulent discharge, tenderness of wounds or endovascular catheter sites, and fever (60.8%) were the most common clinical manifestations of MRSA infection. Respiratory distress and septic shock occurred in 28.4% and 6.8% of cases, respectively. Of 74 patients with MRSA infection and 37 patients with MRSA colonization, 68 (91.9%) and 21 (56.8%) patients received antibiotics in the preceding six weeks, respectively (P<0.0001, odds ratio 8.6, CI 2.7 to 28.7). Of 111 patients with MRSA infection or colonization, 53 (47.7%) had at least one comorbidity, 39 (35.1%) had one comorbidity, and 14 (12.6%) had two comorbidities.
Table 1.
Characteristics | Number of patients (%) |
---|---|
Nosocomial acquisition | 83 (74.8) |
Community acquisition | 28 (25.2) |
Comorbidities | 53 (47.7) |
Diabetes mellitus | 24 (21.6) |
Malignancy | 12 (10.8) |
End-stage renal failure | 10 (9.0) |
Cerebrovascular accident | 8 (7.2) |
Heart failure | 7 (6.3) |
Chronic obstructive pulmonary disease | 5 (4.5) |
HIV infection | 2 (1.8) |
Past history of MRSA infection or colonization | 21 (18.9) |
Previous hospitalization | 20 (18.0) |
Unit | |
Medical ward | 30 (27) |
Paediatrics (medical and surgical) ward | 23 (20.7) |
Outpatient department | 20 (18) |
Surgical ward | 19 (17.1) |
Intensive care unit | 12 (10.8) |
Neonatal intensive care unit | 7 (6.3) |
Clinical significance | |
MRSA infection | 74 (66.7) |
MRSA colonization | 37 (33.3) |
Type of infection (n=74 patients) | |
Central venous catheter infection | 10 (13.5) |
Peripheral venous line infection | 5 (6.8) |
Surgical site infection | 23 (31.1) |
Pneumonia | 20 (27) |
Urinary tract infection | 3 (4.1) |
Others | 13 (17.6) |
Bacteremia (n=74 patients) | 20 (27) |
Clinical manifestations of MRSA infections | |
(n=74 patients) | |
Fever | 45 (60.8) |
Shock | 5 (6.8) |
Respiratory distress | 21 (28.4) |
Local signs | 51 (68.9) |
Outcome (n=74 patients) | |
Recovery | 29 (39.2) |
Death due to MRSA infection | 28 (37.8) |
Death due to other causes | 17 (23) |
Twenty-nine of 74 (39.2%) patients with MRSA infections recovered completely from their infections; 21 (28.4%) patients had an uneventful recovery, whereas the remaining eight (10.8%) patients recovered following complications, such as septic shock and/or respiratory failure requiring mechanical ventilation. The total mortality of patients with MRSA infection was 60.8% (45 of 74); 37.8% (28 of 74) died as a result of MRSA infection and 23% (17 of 74) as a result of other diseases.
DISCUSSION
The present study at the King Abdulaziz University Hospital demonstrated a high prevalence of MRSA (38% of all S aureus isolates). The prevalence has increased gradually from less than 2% in 1988 (unpublished data) to the current rate of 38%. The organism affected all age groups, but almost half (45.9%) of the patients were in the 'extremes of age' group (younger than one or older than 60 years). There was no predilection for any sex or nationality. Three-quarters (74.8%) of cases were nosocomial, and the remainder (25.2%) were community acquired. The prevalence was highest in the medical ward (27%), followed by the paediatrics combined medical and surgical ward (20.7%), the outpatient department (18%), the adult surgical ward (17.1%), the intensive care unit (10.8%) and the neonatal intensive care unit (6.3%). Approximately two-thirds (66.7%) of cases represented infection and one-third (33.3%) represented colonization. This high infection to colonization ratio was similar to what has been observed by other researchers (29). For instance, in an American MRSA outbreak, 260 of 286 (90.9%) affected patients were infected and not simply colonized (29). Health care facilities that routinely perform MRSA surveillance cultures, which were not undertaken at the King Abdulaziz University Hospital during this study period, obviously have a substantially lower infection to colonization ratio due to the detection of more colonized patients. Therefore, this information is essential for the appropriate comparison of the MRSA prevalence and infection to colonization ratio of different centres.
Once confined mainly to hospitals, MRSA has recently been increasingly implicated in community-acquired infections and colonization in patients with predisposing risk factors such as recent contact with a health care facility or nursing home residence, or parenteral substance abuse (3-7), as well as in patients without any recognized predisposing risk factors (7-12). For instance, in two hospitals in the United States in the early 1990s, 28% to 67% of patients with MRSA colonization had probable community acquisition (30,31). In five Canadian tertiary acute care teaching hospitals in three provinces, patients with MRSA isolates present at admission accounted for 62% of MRSA isolations from 1990 to 1992 (11). In a university hospital in the United States, 36 of 87 (41%) patients with MRSA had community acquisition; of those, eight (22%) had no identified risk factors (32). In a paediatric hospital in the United States, eight and 35 cases of community-acquired MRSA infections were identified in the time periods of 1988 to 1990 and 1993 to 1995, respectively. One (12.5%) and 25 (71.4%) cases had no identified risk factors, respectively, and the prevalence of community-acquired MRSA without identified risk increased from 0.1/1000 admissions in 1988 to 1990 to 2.6/1000 admissions in 1993 to 1995 (12). At the King Abdulaziz University Hospital, the prevalence of community acquisition of MRSA (25.2% or 1.5/1000 admissions) was moderately high compared with published data. These studies, collectively, suggest that MRSA may be more widespread in the general population than has been previously appreciated.
Risk factors that have been associated with MRSA acquisition include older age, prolonged hospitalization, prior antibiotic therapy, more severe underlying disease and degree of disability, surgical procedures, presence in an intensive care or burn unit, having a surgical wound infection, intravascular devices, mechanical ventilation, tracheostomy, pressure ulcers, or exposure to other infected or colonized individuals (1,2,33-38). Not only does antibiotic therapy predispose patients to colonization with MRSA, but it also increases the risk of invasive disease and infection, as demonstrated by the present study, in which significantly more patients with MRSA infection than those with MRSA colonization received antibiotics before positive MRSA culture (91.9% versus 56.8%, P<0.0001). Other host factors associated with progression from colonization to infection include recent hospitalization, preceding surgical or wound debridement, and the number of invasive procedures (39).
The body sites that were most frequently affected by overt MRSA infection were surgical sites (infections, 31.1%), the chest (pneumonia, 27%), and endovascular catheter sites (infections, 20.3%). Approximately 25% of patients with MRSA infections had bacteremia, but only 6.8% had overt septic shock. The total mortality of patients with MRSA infections was high (60.8%), as was the mortality attributable to MRSA infection (37.8%). It was generally believed that MRSA strains were not more virulent than methicillin-susceptible S aureus (MSSA) strains (20,40,41). Recent data, however, suggest that MRSA bacteremia is associated with a significantly higher mortality rate than MSSA bacteremia (42-44). For instance, Romero-Vivas et al (42) compared 100 cases of MSSA bacteremia and 84 cases of MRSA bacteremia; the mortality rates were 32% and 58.3%, respectively (P<0.01), and methicillin resistance was found to be independently associated with mortality.
CONCLUSIONS
The prevalence of MRSA is high and rapidly increasing at the King Abdulaziz University Hospital, as it is worldwide. One can foresee a time in the near future when the majority of S aureus isolates is resistant to methicillin, as happened with penicillin, a drug to which almost all isolates of S aureus are resistant. Attempts to control the spread of MRSA in hospitals should continue with reinforcement of hygienic precautions and infection control measures (45). Hospitals should also develop policies to restrict the use of antibiotics and to establish monitoring systems for rapid identification of epidemics and determination of factors that are responsible for spread and colonization to allow for a more targeted approach.
References
- 1.Thompson RL, Cabezudo I, Wenzel RP. Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus Ann Intern Med 1982;97:309-17. [DOI] [PubMed] [Google Scholar]
- 2.Boyce JM. Methicillin-resistant Staphylococcus aureus: Detection, epidemiology, and control measures. Infect Dis Clin North Am 1989;3:901-13. [PubMed] [Google Scholar]
- 3.Saravolatz LD, Markowitz N, Arking L, Pohlod D, Fisher E. MRSA: Epidemiologic observations during a community-acquired outbreak. Ann Intern Med 1982;96:11-6. [DOI] [PubMed] [Google Scholar]
- 4.Saravolatz LD, Pohlod DJ, Arking LM. Community-acquired methicillin-resistant Staphylococcus aureus infections: A new source for nosocomial outbreaks. Ann Intern Med 1982;97:325-9. [DOI] [PubMed] [Google Scholar]
- 5.Levine DP, Cushing RD, Jui J, Brown WJ. Community-acquired MRSA endocarditis in the Detroit Medical Center. Ann Intern Med 1982;97:330-8. [DOI] [PubMed] [Google Scholar]
- 6.Craven DE, Rixinger AI, Goularte TA, McCabe WR. Methicillin-resistant Staphylococcus aureus bacteremia linked to intravenous drug abusers using a 'shooting gallery'. Am J Med 1986;80:770-5. [DOI] [PubMed] [Google Scholar]
- 7.Moreno F, Crisp C, Jorgensen JH, Patterson JE. Methicillin-resistant Staphylococcus aureus as a community organism. Clin Infect Dis 1995;21:1308-12. [DOI] [PubMed] [Google Scholar]
- 8.Berman DS, Eisner W. Community-acquired methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1993;329:1896. [DOI] [PubMed] [Google Scholar]
- 9.Pate KR, Nolan RL, Bannerman TL, Feldman S. Methicillin-resistant Staphylococcus aureus in the community. Lancet 1995;346:978. [DOI] [PubMed] [Google Scholar]
- 10.Hollis RJ, Barr JL, Doebbeling BN, Pfaller MA, Wenzel RP. Familial carriage of methicillin-resistant Staphylococcus aureus and subsequent infection in a premature neonate. Clin Infect Dis 1995;21:328-32. [DOI] [PubMed] [Google Scholar]
- 11.Embil J, Ramotar K, Romance L, et al. Methicillin-resistant Staphylococcus aureus in tertiary care institutions on the Canadian prairies 1990-92. Infect Control Hosp Epidemiol 1994;15:646-51. [DOI] [PubMed] [Google Scholar]
- 12.Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998;279:593-8. [DOI] [PubMed] [Google Scholar]
- 13.Boyce JM. Increasing prevalence of methicillin-resistant Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol 1990;11:639-42. [DOI] [PubMed] [Google Scholar]
- 14.Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994;13:50-5. [DOI] [PubMed] [Google Scholar]
- 15.Cookson BD. Aspects of the epidemiology of MRSA in Europe. J Chemother 1995;7(Suppl 3):93-8. [PubMed] [Google Scholar]
- 16.Oguri T. The incidence and antimicrobial susceptibility of clinical isolates of MRSA from 1988 to 1990, from the results of 26 clinical laboratories in Tokyo and the surrounding area. Jap J Clin Med 1992;50:952-60. [PubMed] [Google Scholar]
- 17.Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. JAMA 1995;274:639-44. [PubMed] [Google Scholar]
- 18.Vandenbroucke-Grauls C. Management of methicillin-resistant Staphylococcus aureus in the Netherlands. Rev Med Microbiol 1998;9:109-16. [Google Scholar]
- 19.Panlilio AL, Culver DH, Gaynes RP, et al. Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992;13:582-6. [DOI] [PubMed] [Google Scholar]
- 20.Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339:520-32. [DOI] [PubMed] [Google Scholar]
- 21.Gaynes R, Culver D, National Nosocomial Infections Surveillance System. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) in the United States, 1975-1996. The IDSA 35th Annual Meeting. San Francisco, September 13-16, 1997. (Abstr 727)
- 22.Speller DCE, Johnson AP, James D, et al. Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989-95. Lancet 1997;350:323-5. [DOI] [PubMed] [Google Scholar]
- 23.Mayor S. England sets standards to reduce hospital acquired infection. BMJ 1999;319:1392. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Hanifah YA, Hiramatsu K, Yokota T. Characterization of methicillin-resistant Staphylococcus aureus associated with nosocomial infection in the University Hospital, Kuala Lumpur. J Hosp Infect 1992;21:15-28. [DOI] [PubMed] [Google Scholar]
- 25.Geyid A, Lemeneh Y. The incidence of methicillin-resistant Staphylococcus aureus strains in clinical specimens in relation to their beta-lactamase producing and multiple-drug resistance properties in Addis Ababa. Ethiop Med J 1991;29:149-61. [PubMed] [Google Scholar]
- 26.Hart CA, Kariuki S. Antimicrobial resistance in developing countries. BMJ 1998;317:647-50. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests. Approved Standard M2-A5. Villanova: National Committee for Clinical Laboratory Standards, 1993.
- 28.National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3. Villanova: National Committee for Clinical Laboratory Standards, 1993.
- 29.Myers JP, Linnemann CC. Bacteraemia due to methicillin-resistant Staphylococcus aureus J Infect Dis 1982;145:532-6. [DOI] [PubMed] [Google Scholar]
- 30.Linnemann CC, Moore P, Staneck JL, Pfaller MA. Reemergence of epidemic methicillin-resistant Staphylococcus aureus in a general hospital associated with changing staphylococcal strains. Am J Med 1991;91(Suppl 3B):238S-44S. [DOI] [PubMed] [Google Scholar]
- 31.Nettleman MD, Trilla A, Fredrickson M, Pfaller MA. Assigning responsibility: Using feedback to achieve sustained control of methicillin-resistant Staphylococcus aureus Am J Med 1991;91(Suppl 3B):228S-32S. [DOI] [PubMed] [Google Scholar]
- 32.Layton MC, Hierholzer WJ, Patterson JE. The evolving epidemiology of methicillin-resistant Staphylococcus aureus at a university hospital. Infect Control Hosp Epidemiol 1995;16:12-7. [DOI] [PubMed] [Google Scholar]
- 33.Crossley K, Loesch D, Landesman B, et al. An outbreak of infection caused by strains of Staphylococcus aureus resistant to methicillin and aminoglycosides. I. Clinical studies. J Infect Dis 1979;139:273-9. [DOI] [PubMed] [Google Scholar]
- 34.Strausbaugh LJ, Jacobson C, Sewell DL, Potter S, Ward TT. Methicillin-resistant Staphylococcus aureus in extended-care facilities: Experiences in a veterans' affairs nursing home and a review of the literature. Infect Control Hosp Epidemiol 1991;12:36-45. [DOI] [PubMed] [Google Scholar]
- 35.Peacock JE, Marsik FJ, Wenzel RP. Methicillin-resistant Staphylococcus aureus: Introduction and spread within a hospital. Ann Intern Med 1980;93:526-32. [DOI] [PubMed] [Google Scholar]
- 36.Linnemann CC Jr, Mason M, Moore P, Korfhagen TR, Staneck JL. Methicillin-resistant Staphylococcus aureus: Experience in a general hospital over four years. Am J Epidemiol 1982;115:941-50. [DOI] [PubMed] [Google Scholar]
- 37.Cohen SH, Morita MM, Bradford M. A seven-year experience with methicillin-resistant Staphylococcus aureus Am J Med 1991;91(Suppl 3B):233S-7S. [DOI] [PubMed] [Google Scholar]
- 38.Coello R, Jimenez J, Garcia M, et al. Prospective study of infection, colonization and carriage of methicillin-resistant Staphylococcus aureus in an outbreak affecting 990 patients. Eur J Clin Micro Infect Dis 1994;13:74-81. [DOI] [PubMed] [Google Scholar]
- 39.Longfield JN, Townsend TR, Cruess DF, et al. Methicillin-resistant Staphylococcus aureus (MRSA): Risk and outcome of colonized vs. infected patients. Infect Control 1985;6:445-50. [DOI] [PubMed] [Google Scholar]
- 40.French GL, Cheng AF, Ling JM, Mo P, Donnan S. Hong Kong strains of methicillin-resistant and methicillin-sensitive Staphylococcus aureus have similar virulence. J Hosp Infect 1990;15:117-25. [DOI] [PubMed] [Google Scholar]
- 41.Harbarth S, Rutschmann O, Sudre P, Pittet D. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus Arch Intern Med 1998;158:182-9. [DOI] [PubMed] [Google Scholar]
- 42.Romero-Vivas J, Rubio M, Fernandez C, Picazo JJ. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus Clin Infect Dis 1995;21:1417-23. [DOI] [PubMed] [Google Scholar]
- 43.Conterno LO, Wey SB, Castelo A. Risk factors for mortality in Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 1998;19:32-7. [DOI] [PubMed] [Google Scholar]
- 44.Blot S, Vandewoude K, Colardyn F. Staphylococcus aureus infections. N Engl J Med 1998;339:2025-7. [DOI] [PubMed] [Google Scholar]
- 45.Mulligan ME, Murray-Leisure KA, Ribner BS, et al. Methicillin-resistant Staphylococcus aureus: A consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993;94:313-28. [DOI] [PubMed] [Google Scholar]